[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sjogrens-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sjogrens-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,70,116,140,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100546267","phase-1-dose-escalation-trial-of-mesenchymal-stromal-cells-in-patients-with-medical-xerostomia-100546267",false,"NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","Inclusion Criteria:\n\n* Xerostomia, defined as an unstimulated salivary flow \\\u003C1.2 mL in 5 minutes documented at any time following xerostomia diagnosis and prior to enrollment\n* Xerostomia not resulting from radiotherapy (medical xerostomia)\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 28 calendar days of enrollment):\n\n  * Hgb ≥ 9 g\u002FdL (5.58 mmol\u002FL)\n  * Platelets ≥ 100,000\u002FµL\n  * ANC ≥ 1000\u002FµL\n  * Lymphocytes ≥ 800\u002FµL\n  * PT\u002FINR and PTT within normal limits based on age\u002Fsex\n\nExclusion Criteria:\n\n* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HbA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms and are still on diuretic therapy and the referring provider believes the dryness symptoms are driven by diuretic use\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study","ALL","18 Years","90 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth.\n\nParticipants will:\n\n* have bone marrow collected using a needle\n* undergo a salivary gland ultrasound\n* complete questionnaires\n* receive an injection of the bone marrow cells into a salivary gland",[27,28,29],"Xerostomia","Graft-versus-host-disease","Sjogren's Disease","RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2024-10-04",{"date":38,"type":21},"2028-11",{"name":40,"class":41},"University of Wisconsin, Madison","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100651513","phase-2-a-study-to-assess-efficacy-and-safety-of-efgartigimod-in-adults-with-sjogrens-disease-associated-sensorimotor-polyneuropathy-or-sensory-polyneuropathy-serenity-100651513","NCT07760818","A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)","A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy","SERENITY","Inclusion Criteria:\n\n* Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF\n* Meets the following SjD criteria: Fulfilled American College of Rheumatology and the European Alliance of Associations for Rheumatology classification 2016 SjD criteria before screening; Moderate-to-severe disease defined as a ESSDAI ≥ 5 or clinESSDAI ≥ 6 with PNS domain score of ≥ 5 (ie, a score of at least low activity) at screening; Anti-Ro\u002FSS-A positive at a central laboratory at screening\n* Meets the following SjD-associated polyneuropathy criteria: Diagnosis of SjD-associated SMPN, SPN or sensory ganglionopathy, with neuropathy duration ≤ 5 years at screening and signs of active neuropathic disease development within the last 12 months; patients with co-existing SjD-associated small fiber neuropathy are eligible; No alternative diagnosis of neuropathy etiology; Total mTCNS ≥ 6 at screening; mTCNS sensory test score \\\u003Clevel 3 at screening (does not apply to sensory ganglionopathy cohort where any severity is acceptable)\n\nExclusion Criteria:\n\n* Besides the indication under study, known medical conditions that would interfere with an accurate assessment of clinical symptoms of SjD-associated SMPN or SPN or gangliopathy, confound the study results, or puts the participant at undue risk.\n* Associated (also known as secondary) SjD, defined as overlap with another autoimmune rheumatic or systemic inflammatory condition (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or idiopathic inflammatory myopathy).\n* Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.\n* An alternative etiology for SMPN\u002FSPN\u002Fsensory ganglionopathy or insufficient evidence of the diagnosis.\n* Any severe SjD manifestation or other health condition not adequately controlled at screening or baseline that may put the participant at undue risk based on the investigator's opinion.\n* Comorbidities (eg, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic (oral, IV, or IM) glucocorticoids within the previous 12 months.\n* History of malignancy unless considered cured by adequate treatment with no evidence of recurrence for ≥ 3 years; before first IMP administration.",{"count":52,"type":21},75,[54],"PHASE2","This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.",[57,58],"Sjogrens Disease","Primary Sjögren's Syndrome Painful Sensory Neuropathies","NOT_YET_RECRUITING","2026-08-07",{"date":62,"type":34},"2026-08-12",{"date":64,"type":21},"2026-08-14",{"date":66,"type":21},"2029-07-28",{"name":68,"class":69},"argenx","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100592260","phase-2-allonk-an-allogeneic-non-genetically-modified-cord-blood-derived-nk-cell-therapy-in-combination-with-rituximab-studied-in-relapsing-forms-of-b-cell-dependent-rheumatologic-diseases-100592260","NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.","An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases","For Subjects with Refractory Rheumatoid Arthritis (RA):\n\n* Documented diagnosis of RA, meeting the 2010 ACR\u002FEULAR classification criteria.\n* Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.\n* High-sensitivity C-reactive protein (hs-CRP) \\> 3 mg\u002FL or Erythrocyte Sedimentation Rate (ESR) \\> 28 mm\u002Fhr.\n* Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.\n* Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.\n\nFor subjects with Sjögren's Disease (SjD)\n\n* Prior diagnosis of Primary SjD as per 2016 ACR\u002FEULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.\n* Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) \\> 6.\n* Salivary Flow Rate \\> 0.1 mL\u002Fmin on stimulation.\n\nFor subjects with Idiopathic Inflammatory Myopathies (IIMs)\n\n* Presence of a positive autoantibody (ANA \\>1:80 or RNP or SSA\u002FSSB or other myositis specific autoantibodies.\n* Refractory IIM as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.\n* Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.\n\nFor Subjects with Systemic Sclerosis (SSc)\n\n* Diagnosis of SSc in accordance with the ACR\u002FEULAR 2013 classification.\n* Modified Rodnan skin score (mRSS) \\> 10.\n* Initial confirmatory diagnosis within 8 years of screening.\n* Refractory SSc as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.",{"count":78,"type":21},90,[54],"A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.",[82,83,84,85,86,87,88,89,57],"Refractory Rheumatoid Arthritis (RA)","Idiopathic Inflammatory Myopathies (IIMs)","Systemic Sclerosis (SSc)","Rheumatoid Arthritis (RA","IIM","Myositis","Scleroderma","Sjogren Syndrome",[91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Refractory Rheumatoid Arthritis","AlloNK","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","Sjögren's Disease","Refractory RA","Cell Therapy","Allogeneic NK Cells","Allogeneic Cell Therapy","non-genetically modified","rituximab","cord blood cells","ADCC enhancement","outpatient","community","2026-07-29",{"date":108,"type":34},"2026-07-31",{"date":110,"type":34},"2025-07-09",{"date":112,"type":21},"2029-01",{"name":114,"class":69},"Artiva Biotherapeutics, Inc.",52,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100649228","phase-1-a-study-of-atg-201-in-adult-participants-with-autoimmune-diseases-100649228","NCT07732309","A Study of ATG-201 in Adult Participants With Autoimmune Diseases","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of ATG-201 in Adult Participants With Autoimmune Diseases","ATTRACT","Inclusion Criteria:\n\n1. Participants who give consent to this study participation and sign informed consent form.\n2. Participants at least 18 years of age inclusive at screening visit.\n3. Must be able to adhere to the study visit schedule and other protocol .requirements.\n4. Female of childbearing potential must agree to use adequate contraceptive measures from 28 days before starting study treatment to until 48 weeks after last dose of treatment, not breastfeeding, and have a negative serum pregnancy test at screening.\n5. Male participants must agree to use an effective barrier method of contraception during sexual contact with a female of childbearing potential during screening and throughout the study until 48 weeks after the final dose of study treatment.\n\nSLE: subjects:\n\n1. Have a confirmed diagnosis of SLE and meet the 2019 European League Against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) classification criteria at screening.\n2. Have active SLE disease.\n3. Have had previous treatment failure.\n\nExclusion Criteria:\n\n1. Intolerance or allergy to the investigational product, or to any component thereof, or to any concomitant medications that may be used in the study (e.g., tocilizumab).\n2. Presence of central nervous system disorders of either autoimmune or non-autoimmune etiology, including but not limited to: epilepsy, psychotic disorders, organic brain syndrome, cerebrovascular accident, encephalitis, or central nervous system vasculitis.\n3. Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening.\n4. Severe (requiring oxygen support) or rapidly progressing interstitial lung disease.\n5. Uncontrolled other diseases: history or clinical evidence of active significant acute or chronic diseases (i.e., cardiovascular, pulmonary, untreated hypertension, anemia, gastrointestinal, hepatic, renal, neurological, cancer, or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.\n6. History of a major organ transplant (e.g. heart, lung, renal, liver) or hematopoietic stem cell\u002Fmarrow transplant.\n7. Have a planned surgical procedure, or a history of any other medical disease, or laboratory abnormalities, or conditions which would make the participant (in the opinion of the investigator) unsuitable for the study.\n8. Received intravenous immunoglobulin, plasmapheresis, hemodialysis, intravenous cyclophosphamide, or high dose prednisone and its equivalents (\\>60 mg\u002Fday) within 2 months prior to screening.\n9. Live or attenuated vaccine within 28 days prior to screening or during screening.\n10. Participants who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months or who, in the investigator's opinion, pose a significant suicide risk.\n11. The participant has an abnormality on 12-lead electrocardiogram at screening which is clinically significant in the opinion of the investigator, and which could confound the results of the study.",{"count":125,"type":21},149,[24],"This is a phase I, open-label study of ATG-201 in participants with autoimmune diseases.",[129,84,29],"Systemic Lupus Erythematosus","2026-07-24",{"date":132,"type":34},"2026-07-28",{"date":134,"type":21},"2026-09-01",{"date":136,"type":21},"2029-06-01",{"name":138,"class":69},"Antengene Biologics Limited",22,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":42},"100610558","phase-1-om336-in-seropositive-autoimmune-diseases-100610558","NCT07229144","OM336 in Seropositive Autoimmune Diseases","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy","Key Inclusion Criteria:\n\n* Diagnosis of active seropositive autoimmune disease\n* Relapsed\u002Frefractory after ≥2 prior\u002Fongoing treatments\n* Body weight ≥ 50 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery within 3 months of screening or planned during the study\n* Pregnant or breastfeeding","75 Years",{"count":149,"type":21},39,[24],"An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.",[57,153],"Idiopathic Inflammatory Myopathy (IIM)",[155,156],"OM336","Ouro","2026-06-11",{"date":159,"type":34},"2026-06-15",{"date":161,"type":34},"2025-10-01",{"date":163,"type":21},"2028-03",{"name":165,"class":69},"Ouro Medicines",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":42},"100634800","explanatory-factors-and-predictors-of-fatigue-in-patients-with-sjgrens-disease-a-3-month-longitudinal-study-100634800","NCT07544394","Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study","Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-Month Longitudinal Study","Inclusion Criteria:\n\n* Diagnosis of Sjögren's syndrome\n* Age ≥ 18 years\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of severe somatic or psychiatric disorders\n* Presence of malignancy\n* Pregnancy\n* Refusal to participate or inability to provide written informed consent",{"count":174,"type":21},100,"OBSERVATIONAL","This prospective longitudinal study will be conducted in patients diagnosed with Sjögren's disease who are followed at the rheumatology outpatient clinic of Kahramanmaras Sutcu Imam University Medical Faculty Hospital. Demographic and clinical data will be collected from routine clinical assessments and medical records, including laboratory results obtained during standard care.\n\nParticipants will undergo evaluation of pressure pain threshold using a digital algometer and complete validated questionnaires assessing fatigue, disease activity, patient-reported symptoms, anxiety and depression, pain catastrophizing, sleep quality, and physical activity level.\n\nAll assessments will be performed at baseline and repeated at follow-up visits approximately 3 months later.",[29,178],"Fatigue","2026-04-22",{"date":181,"type":34},"2026-04-27",{"date":183,"type":34},"2026-04-20",{"date":185,"type":21},"2028-04-20",{"name":187,"class":41},"Kahramanmaras Sutcu Imam University"]